APTO News and Press, Aptose Biosciences Inc. From 09/27/18

Aptose Biosciences (NASDAQ: APTO ) announces that the European Patent Office has issued European Patent No. EP2940014B1 for CG-806, a highly potent oral small molecule being developed for acute myeloid leukemia (AML), B cell and other hematologic malignancies. More news on: Aptose B...

SAN DIEGO, TORONTO and SEOUL, South Korea, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the European Patent Office (“EPO”) has issued European Patent No. EP2940...